Advertisement

Topics

Aimmune Lays Foundations In Europe For Lead Peanut Allergy Therapeutic

08:52 EDT 26 Mar 2019 | SCRIP

With Aimmune’s AR101 oral immunotherapeutic nearing the market in the EU and US, the company sketches out its European business...

      

Related Stories

 

Original Article: Aimmune Lays Foundations In Europe For Lead Peanut Allergy Therapeutic

NEXT ARTICLE

More From BioPortfolio on "Aimmune Lays Foundations In Europe For Lead Peanut Allergy Therapeutic"

Advertisement
Quick Search
Advertisement
Advertisement